Jabbour-Leung, N. A., Chen, X., Bui, T., Jiang, Y., Yang, D., Vijayaraghavan, S., . . . Keyomarsi, K. (2016). Sequential combination therapy of CDK inhibition and doxorubicin is synthetically lethal in p53-mutant triple-negative breast cancer. Mol Cancer Ther.

Jabbour-Leung, Natalie A., Xian Chen, Tuyen Bui, Yufeng Jiang, Dong Yang, Smruthi Vijayaraghavan, Mark J. McArthur, Kelly K. Hunt, و Khandan Keyomarsi. "Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in P53-mutant Triple-negative Breast Cancer." Mol Cancer Ther 2016.

Jabbour-Leung, Natalie A., et al. "Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in P53-mutant Triple-negative Breast Cancer." Mol Cancer Ther 2016.